FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3127329393> ?p ?o ?g. }

• W3127329393 endingPage "681" @default.
• W3127329393 startingPage "671" @default.
• W3127329393 abstract "BackgroundA heterologous recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), showed a good safety profile and induced strong humoral and cellular immune responses in participants in phase 1/2 clinical trials. Here, we report preliminary results on the efficacy and safety of Gam-COVID-Vac from the interim analysis of this phase 3 trial.MethodsWe did a randomised, double-blind, placebo-controlled, phase 3 trial at 25 hospitals and polyclinics in Moscow, Russia. We included participants aged at least 18 years, with negative SARS-CoV-2 PCR and IgG and IgM tests, no infectious diseases in the 14 days before enrolment, and no other vaccinations in the 30 days before enrolment. Participants were randomly assigned (3:1) to receive vaccine or placebo, with stratification by age group. Investigators, participants, and all study staff were masked to group assignment. The vaccine was administered (0·5 mL/dose) intramuscularly in a prime-boost regimen: a 21-day interval between the first dose (rAd26) and the second dose (rAd5), both vectors carrying the gene for the full-length SARS-CoV-2 glycoprotein S. The primary outcome was the proportion of participants with PCR-confirmed COVID-19 from day 21 after receiving the first dose. All analyses excluded participants with protocol violations: the primary outcome was assessed in participants who had received two doses of vaccine or placebo, serious adverse events were assessed in all participants who had received at least one dose at the time of database lock, and rare adverse events were assessed in all participants who had received two doses and for whom all available data were verified in the case report form at the time of database lock. The trial is registered at ClinicalTrials.gov (NCT04530396).FindingsBetween Sept 7 and Nov 24, 2020, 21 977 adults were randomly assigned to the vaccine group (n=16 501) or the placebo group (n=5476). 19 866 received two doses of vaccine or placebo and were included in the primary outcome analysis. From 21 days after the first dose of vaccine (the day of dose 2), 16 (0·1%) of 14 964 participants in the vaccine group and 62 (1·3%) of 4902 in the placebo group were confirmed to have COVID-19; vaccine efficacy was 91·6% (95% CI 85·6–95·2). Most reported adverse events were grade 1 (7485 [94·0%] of 7966 total events). 45 (0·3%) of 16 427 participants in the vaccine group and 23 (0·4%) of 5435 participants in the placebo group had serious adverse events; none were considered associated with vaccination, with confirmation from the independent data monitoring committee. Four deaths were reported during the study (three [<0·1%] of 16 427 participants in the vaccine group and one [<0·1%] of 5435 participants in the placebo group), none of which were considered related to the vaccine.InterpretationThis interim analysis of the phase 3 trial of Gam-COVID-Vac showed 91·6% efficacy against COVID-19 and was well tolerated in a large cohort.FundingMoscow City Health Department, Russian Direct Investment Fund, and Sberbank." @default.
• W3127329393 created "2021-02-15" @default.
• W3127329393 creator A5001013377 @default.
• W3127329393 creator A5001156655 @default.
• W3127329393 creator A5002834673 @default.
• W3127329393 creator A5005313486 @default.
• W3127329393 creator A5007583738 @default.
• W3127329393 creator A5007845916 @default.
• W3127329393 creator A5008928332 @default.
• W3127329393 creator A5011890220 @default.
• W3127329393 creator A5015118504 @default.
• W3127329393 creator A5018295805 @default.
• W3127329393 creator A5023512329 @default.
• W3127329393 creator A5030045724 @default.
• W3127329393 creator A5032082442 @default.
• W3127329393 creator A5033849007 @default.
• W3127329393 creator A5035694656 @default.
• W3127329393 creator A5035971548 @default.
• W3127329393 creator A5036628717 @default.
• W3127329393 creator A5042474035 @default.
• W3127329393 creator A5043008094 @default.
• W3127329393 creator A5044751937 @default.
• W3127329393 creator A5045721839 @default.
• W3127329393 creator A5062273340 @default.
• W3127329393 creator A5065610637 @default.
• W3127329393 creator A5067343302 @default.
• W3127329393 creator A5068838749 @default.
• W3127329393 creator A5069724675 @default.
• W3127329393 creator A5070967582 @default.
• W3127329393 creator A5072796711 @default.
• W3127329393 creator A5085732220 @default.
• W3127329393 creator A5089841877 @default.
• W3127329393 creator A5090218998 @default.
• W3127329393 date "2021-02-01" @default.
• W3127329393 modified "2023-10-18" @default.
• W3127329393 title "Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia" @default.
• W3127329393 cites W1972258033 @default.
• W3127329393 cites W1979742563 @default.
• W3127329393 cites W1982712041 @default.
• W3127329393 cites W2095418304 @default.
• W3127329393 cites W2338153609 @default.
• W3127329393 cites W2584009705 @default.
• W3127329393 cites W3075666614 @default.
• W3127329393 cites W3083750089 @default.
• W3127329393 cites W3111255098 @default.
• W3127329393 cites W3111590711 @default.
• W3127329393 doi "https://doi.org/10.1016/s0140-6736(21)00234-8" @default.
• W3127329393 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7852454" @default.
• W3127329393 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33545094" @default.
• W3127329393 hasPublicationYear "2021" @default.
• W3127329393 type Work @default.
• W3127329393 sameAs 3127329393 @default.
• W3127329393 citedByCount "1251" @default.
• W3127329393 countsByYear W31273293932020 @default.
• W3127329393 countsByYear W31273293932021 @default.
• W3127329393 countsByYear W31273293932022 @default.
• W3127329393 countsByYear W31273293932023 @default.
• W3127329393 crossrefType "journal-article" @default.
• W3127329393 hasAuthorship W3127329393A5001013377 @default.
• W3127329393 hasAuthorship W3127329393A5001156655 @default.
• W3127329393 hasAuthorship W3127329393A5002834673 @default.
• W3127329393 hasAuthorship W3127329393A5005313486 @default.
• W3127329393 hasAuthorship W3127329393A5007583738 @default.
• W3127329393 hasAuthorship W3127329393A5007845916 @default.
• W3127329393 hasAuthorship W3127329393A5008928332 @default.
• W3127329393 hasAuthorship W3127329393A5011890220 @default.
• W3127329393 hasAuthorship W3127329393A5015118504 @default.
• W3127329393 hasAuthorship W3127329393A5018295805 @default.
• W3127329393 hasAuthorship W3127329393A5023512329 @default.
• W3127329393 hasAuthorship W3127329393A5030045724 @default.
• W3127329393 hasAuthorship W3127329393A5032082442 @default.
• W3127329393 hasAuthorship W3127329393A5033849007 @default.
• W3127329393 hasAuthorship W3127329393A5035694656 @default.
• W3127329393 hasAuthorship W3127329393A5035971548 @default.
• W3127329393 hasAuthorship W3127329393A5036628717 @default.
• W3127329393 hasAuthorship W3127329393A5042474035 @default.
• W3127329393 hasAuthorship W3127329393A5043008094 @default.
• W3127329393 hasAuthorship W3127329393A5044751937 @default.
• W3127329393 hasAuthorship W3127329393A5045721839 @default.
• W3127329393 hasAuthorship W3127329393A5062273340 @default.
• W3127329393 hasAuthorship W3127329393A5065610637 @default.
• W3127329393 hasAuthorship W3127329393A5067343302 @default.
• W3127329393 hasAuthorship W3127329393A5068838749 @default.
• W3127329393 hasAuthorship W3127329393A5069724675 @default.
• W3127329393 hasAuthorship W3127329393A5070967582 @default.
• W3127329393 hasAuthorship W3127329393A5072796711 @default.
• W3127329393 hasAuthorship W3127329393A5085732220 @default.
• W3127329393 hasAuthorship W3127329393A5089841877 @default.
• W3127329393 hasAuthorship W3127329393A5090218998 @default.
• W3127329393 hasBestOaLocation W31273293931 @default.
• W3127329393 hasConcept C126322002 @default.
• W3127329393 hasConcept C142724271 @default.
• W3127329393 hasConcept C168563851 @default.
• W3127329393 hasConcept C187212893 @default.
• W3127329393 hasConcept C197934379 @default.
• W3127329393 hasConcept C203014093 @default.
• W3127329393 hasConcept C204787440 @default.
• W3127329393 hasConcept C22070199 @default.

• next